Share This Page
Drug Price Trends for NDC 71336-1001
✉ Email this page to a colleague
Average Pharmacy Cost for 71336-1001
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 71336-1001
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 71336-1001
Introduction
The pharmaceutical landscape surrounding NDC 71336-1001 is characterized by its clinical application, patent status, competitive dynamics, and pricing trends. As a key factor influencing healthcare decision-making, understanding these facets aids stakeholders—including manufacturers, payers, and healthcare providers—in navigating market opportunities and pricing strategies.
Product Overview
NDC 71336-1001 is identified as Vanisol (Vancomycin Hydrochloride) Injection. Vancomycin belongs to the glycopeptide antibiotic class, utilized primarily for severe bacterial infections caused by methicillin-resistant Staphylococcus aureus (MRSA) and other Gram-positive pathogens (FDA, 2023). Its clinical relevance maintains steady demand within hospital settings, particularly in intensive care units and infectious disease management.
Regulatory and Patent Status
Vanisol’s original patent expired years ago, enabling generic entry, which has intensified market competition. Patent fragility and biosimilar entries influence pricing dynamics. Specific patent protection for the formulation contained within NDC 71336-1001 remains inactive, supporting a competitive landscape among generic manufacturers.
Market Dynamics
Market Size and Demand Trends
The global vancomycin market was valued at approximately $1.2 billion in 2022 and is forecasted to grow at a compound annual growth rate (CAGR) of around 4.5% through 2030 (Grand View Research, 2023). The pneumonia and bloodstream infection segments dominate demand. Hospital procurement protocols favor injections like Vanisol due to administration efficacy and resistance considerations.
Key Market Players
Major generic manufacturers, such as Sandoz, Pfizer, and Teva, produce vancomycin formulations. Certain branded products—like Vancocin by Fresenius Kabi—continue to command premium pricing, particularly for specific formulations and packaging.
Geographical Market Variations
North America remains the largest market, driven by high healthcare expenditures, stringent infection control practices, and robust hospital procurement. Europe and Asia-Pacific follow, with expanding healthcare access and rising prevalence of resistant infections augmenting demand.
Pricing Trends and Projections
Current Pricing Landscape
The retail price for a standard vial of vancomycin (e.g., 500 mg) in the U.S. averages between $15 to $30 for generics, depending on supplier and packaging (GoodRx, 2023). Hospital procurement prices are often negotiated and subject to volume discounts, generally below retail levels, maintaining the medication’s cost-effectiveness in clinical settings.
Factors Influencing Future Prices
-
Generic Competition: Increased entry after patent expiry has exerted downward pressure on prices.
-
Supply Chain Dynamics: Manufacturing capacity, raw material availability, and geopolitical factors introduce variability.
-
Regulatory Environment: Stringent quality standards and potential for new formulations influence market entry and pricing strategies.
-
Resistance and Usage Trends: Rising antimicrobial resistance (AMR) could alter demand, impacting pricing dynamics.
Price Projection Outlook
Over the next five years, average prices for vancomycin injections like NDC 71336-1001 are expected to decrease marginally by 10-15% due to intensified generic competition. However, hospital procurement arrangements and potential supply chain constraints may temper declines, resulting in stabilized prices at current levels, particularly in high-volume settings.
In emerging markets, prices are generally lower due to local manufacturing and regulatory factors, but global price parity may narrow as international standards evolve.
Market Challenges and Opportunities
Challenges
- Antimicrobial Stewardship: Increased focus on optimal antibiotic use could influence prescribing patterns, potentially reducing unnecessary utilization.
- Resistance Development: Escalating resistance may limit vancomycin’s efficacy, prompting the need for combination therapies and alternative agents.
- Regulatory Scrutiny: Stringent approval and labeling processes could impact market accessibility and pricing strategies.
Opportunities
- Formulation Innovations: Developing formulations with extended stability or adjunct therapies can command premium pricing.
- Market Expansion: Addressing unmet needs in developing economies offers growth potential, especially if affordability improves.
- Partnerships: Collaborations with healthcare providers and payers can facilitate favorable procurement agreements.
Conclusion
NDC 71336-1001, representing Vanisol, operates in a mature but evolving market landscape. With patent expiries fostering robust generic competition, prices are poised for modest declines, consistent with historical trends. Strategic positioning—focused on cost efficiency, quality assurance, and addressing resistance patterns—will remain crucial for manufacturers seeking sustained market share.
Key Takeaways
- The vancomycin market is stabilizing with increasing generic competition; prices are expected to decline gradually.
- North America dominates demand, but growth opportunities exist in emerging markets.
- Supply chain stability and antimicrobial resistance trends are critical determinants shaping future pricing and market dynamics.
- Innovation in formulations and strategic partnerships can provide differentiation in a commoditized landscape.
- Ongoing antimicrobial stewardship and regulatory changes influence utilization and pricing strategies.
FAQs
1. What factors contribute to the price stabilization of vancomycin injections like NDC 71336-1001?
The entry of multiple generic manufacturers dilutes market power, resulting in price competition. Additionally, hospital procurement practices, negotiated discounts, and supply chain stability sustain price stability.
2. How does antimicrobial resistance impact future demand and pricing?
Increasing resistance to vancomycin may diminish its efficacy, potentially reducing demand or prompting the development of new therapies. Conversely, resistance escalation could sustain or increase demand for existing formulations in the short term.
3. Are there emerging substitutes for vancomycin in treating resistant Gram-positive infections?
Yes. New agents such as telavancin, dalbavancin, and oritavancin offer alternative mechanisms, which could impact vancomycin’s market share and pricing in the future.
4. How do regulatory policies influence the market for NDC 71336-1001?
Regulatory standards ensuring drug quality and safety can affect manufacturing costs and market entry. Stringent approval processes may delay generic manufacturing, influencing pricing dynamics.
5. What opportunities exist for manufacturers of NDC 71336-1001 in developing countries?
Lower manufacturing costs and less regulatory stringency present avenues for expanding access and market share, provided quality standards and local demand are adequately addressed.
Sources
[1] FDA Drug Database, Vancomycin Information, 2023.
[2] Grand View Research, Antibiotics Market Analysis, 2023.
[3] GoodRx, Price Trends for Vancomycin, 2023.
More… ↓
